Lawrence, KS, United States of America

Kevin Frankowski

USPTO Granted Patents = 13 


 

Average Co-Inventor Count = 6.4

ph-index = 1

Forward Citations = 5(Granted Patents)


Location History:

  • Lawrence, KS (US) (2014 - 2020)
  • Pittsboro, NC (US) (2022)
  • Chapel Hill, NC (US) (2023)

Company Filing History:


Years Active: 2014-2024

Loading Chart...
Loading Chart...
Loading Chart...
13 patents (USPTO):Explore Patents

Title: Kevin Frankowski: Innovator in Dopamine Receptor Agonists

Introduction

Kevin Frankowski is a prominent inventor based in Lawrence, KS (US). He has made significant contributions to the field of pharmacology, particularly in the development of selective dopamine receptor agonists. With a total of 13 patents to his name, Frankowski's work has the potential to impact the treatment of various neurodegenerative disorders.

Latest Patents

Among his latest patents are innovative compounds aimed at treating conditions such as Parkinson's disease and related syndromes. His disclosures include selective D3 dopamine receptor agonists and methods of their use. These compounds, defined by specific formulas, are designed to be administered alongside pharmaceutically acceptable carriers. The methods outlined in his patents provide treatment options for patients suffering from dyskinesia, Alzheimer's disease, bipolar disorder, and other cognitive dysfunctions.

Career Highlights

Frankowski has worked with esteemed institutions such as the University of Kansas Medical Center Research Institute and the National Institutes of Health, a component of the US Department of Health & Human Services. His research has focused on developing effective treatments for complex neurological conditions, showcasing his dedication to advancing medical science.

Collaborations

Throughout his career, Frankowski has collaborated with notable colleagues, including Frank John Schoenen and Jeffrey Aube. These partnerships have contributed to the success of his research and the development of his patented inventions.

Conclusion

Kevin Frankowski's innovative work in the field of dopamine receptor agonists highlights his commitment to improving treatment options for patients with neurodegenerative disorders. His contributions continue to pave the way for advancements in pharmacological research and patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…